Peter MacCallum Cancer Centre

Stories

HaemaLogiX doses first patient in KMCAR T-cell multiple myeloma trial

As of August 2026: Trial site and lead sponsor

HaemaLogiX dosed the first patient in its Phase 1 KOALA trial on August 26, and the infusion was well tolerated with no serious adverse events. A second patient is enrolled and set to receive a higher dose at Melbourne's Peter MacCallum Cancer Centre.

Updated Aug 26

PSMA imaging reshapes prostate cancer diagnosis, cutting biopsies in half

New Capabilities

As of May 2026: Co-led PRIMARY2 trial

Every year, roughly 750,000 men in the United States alone undergo prostate biopsies that turn out to be unnecessary. On March 13, 2026, researchers at the European Association of Urology Congress in London presented results from the PRIMARY2 trial showing that a scan using a molecule that binds to prostate cancer cells and makes them glow on imaging cut the need for biopsies nearly in half, without missing dangerous cancers.

Updated May 30